TOP TEN perturbations for 39822_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39822_s_at
Selected probe(set): 207574_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39822_s_at (207574_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
EBNA2 overexpr. study 1 (4h) / control virus transfected EREB2-5 cell sample (24h)
Relative Expression (log2-ratio):4.826578Number of Samples:3 / 3
Experimental | EBNA2 overexpr. study 1 (4h) |
EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 4 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline. | |
Control | control virus transfected EREB2-5 cell sample (24h) |
EREB2-5 cell line stably transfected with control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene. CAT was used as a negative control. Briefly, before the CAT induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline was added. Expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Estrogen withdrawal leads to the inactivation of EBNA2, resulting in cell cycle arrest. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline. |
hepatoblastoma study 1 (NOS) / normal liver tissue
Relative Expression (log2-ratio):-4.4215612Number of Samples:5 / 5
Experimental | hepatoblastoma study 1 (NOS) |
Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
hepatoblastoma study 1 (embryonal) / normal liver tissue
Relative Expression (log2-ratio):-4.34305Number of Samples:7 / 5
Experimental | hepatoblastoma study 1 (embryonal) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):-4.3364363Number of Samples:4 / 4
Experimental | B-CLL study 11 (rolipram) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
Control | rolipram study 4 (normal B-cell; 20uM) |
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
A. fumigatus study 1 / uninfected immature dendritic cell sample
Relative Expression (log2-ratio):4.2523212Number of Samples:2 / 2
Experimental | A. fumigatus study 1 |
5 x 106 immature dendritic cells were cultivated together with 5 x 106 A. fumigatus germ tubes for 6h until isolation of total RNA. | |
Control | uninfected immature dendritic cell sample |
5 x 106 immature dendritic cells were cultivated without fungi. |
hepatoblastoma study 1 (epithelial mixed) / normal liver tissue
Relative Expression (log2-ratio):-4.070116Number of Samples:12 / 5
Experimental | hepatoblastoma study 1 (epithelial mixed) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
EBNA2 overexpr. study 1 (24h) / control virus transfected EREB2-5 cell sample (24h)
Relative Expression (log2-ratio):4.0116835Number of Samples:3 / 3
Experimental | EBNA2 overexpr. study 1 (24h) |
EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline. | |
Control | control virus transfected EREB2-5 cell sample (24h) |
EREB2-5 cell line stably transfected with control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene. CAT was used as a negative control. Briefly, before the CAT induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline was added. Expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Estrogen withdrawal leads to the inactivation of EBNA2, resulting in cell cycle arrest. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline. |
azathioprine study 8 (48h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):3.9889307Number of Samples:2 / 19
Experimental | azathioprine study 8 (48h) |
HepG2 cells exposed to 250μM azathioprine in DMSO solvent for 48 hours. ATC code: | |
Control | vehicle (DMSO) treated HepG2 cell sample |
HepG2 cells exposed to DMSO solvent for 48 hours. |
hepatoblastoma study 1 (fetal) / normal liver tissue
Relative Expression (log2-ratio):-3.9801655Number of Samples:4 / 5
Experimental | hepatoblastoma study 1 (fetal) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):-3.8747587Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal B-cell sample |
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |